Skip to main content

Table 1 Clinical characteristics and outcomes of CLL patients

From: Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELBin an aggressive subset of chronic lymphocytic leukemia in males

Patient's ID

Sex

Age (years)

Binet's stage

FISH Aberrations

Treatment

Matutes

sCD23 PVT

Apoptosis in vitro

B118R

Male

89

A

del(13q14) biallelic; del(11q22)monoallelic

yes

5

160

Resistant

G151R

Male

56

A

del(13q14)biallelic

yes

5

ND

Resistant

E147R

Male

70

A

del(13q14)biallelic; del(17p13)monoallelic

yes

4

ND

Resistant

B138R

Male

65

A

del(13q14)monoallelic

yes

5

ND

Resistant

RM1

Male

81

A

del(13q14)biallelic; del(17p13)monoallelic

yes

5

105

Resistant

RM2

Male

77

A

del(13q14)biallelic

yes

5

400

Resistant

RM3

Male

56

A

del(13q14)monoallelic

yes

4

102

Resistant

RF1

Female

74

A

del(13q14)biallelic; del(17p13)monoallelic

yes

5

443

Resistant

RF2

Female

67

A

del(13q14)monoallelic; del(17p13)monoallelic

yes

5

72

Resistant

RF3

Female

56

A

del(13q14)biallelic; del(17p13)monoallelic

no

5

ND

Resistant

U231R

Female

76

A

del(13q14)monoallelic

yes

5

ND

Resistant

G244S

Female

63

A

del(13q14)monoallelic; del(17p13)monoallelic

no

5

ND

Sensitive

B229S

Female

78

A

del(13q14)monoallelic

no

5

ND

Sensitive

S240S

Female

67

A

no

no

4

ND

Sensitive

SF1

Female

80

A

ND

no

4

70

Sensitive

SF2

Female

62

A

ND

no

4

28

Sensitive

SF3

Female

84

A

ND

no

5

97

Sensitive

SM1

Male

82

A

ND

no

4

52

Sensitive

SM2

Male

65

A

no

no

5

high

Sensitive

SM3

Male

74

A

del(13q14)monoallelic

no

4

low

Sensitive

L130S

Male

77

A

del(13q14)monoallelic

no

4

ND

Sensitive

S152S

Male

77

A

ND

no

4

458

Sensitive

B130S

Male

77

A

del(13q14)monoallelic

yes

4

93

Sensitive

B118S

Male

89

A

del(11q22) monoallelic

yes

4

160

Sensitive

M124S

Male

83

A

ND

no

5

ND

Sensitive

  1. Apoptosis score was established 24 h after cell exposure to 10 Gy of γ-rays. Patients were considered sensitive (S) when the number of apoptotic cells was at least twofold higher in irradiated cells than in non-irradiated at 24 h of cell culture, or as resistant (R) when no difference was observed between irradiated and non-irradiated cells. Patients RM2 and B118S/R shifted from S to R status. Matutes scoring system was established to distinguish CLL from other lymphoproliferative disorders. This score is based on the immunophenotypic analysis of five markers: CD5+, CD23+, FMC7- and CD79b-, weak expression of monotypic κ or λ light chain. A value of 1 is assigned to a given marker with a level typical of CLL, and a total Matutes score at 4 or 5 indicates diagnosis of typical CLL. ND, not determined. Chromosomal aberrations were established by FISH using LSI ATM/LSI p53 and LSI D13S319/LSI 13q34/CEP12 probe sets (Abbott, France) which are complementary to 11q22.3, 17p13.1, 13q14.3, 13q34 and 12p11.1-q11 genome regions, respectively. To be taken into account, the aberration should be present in at least 5% of nuclei.